Diplomat Pharmacy Inc (NYSE:DPLO) has been given an average recommendation of “Hold” by the thirteen brokerages that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $21.25.

DPLO has been the subject of several recent analyst reports. William Blair cut Diplomat Pharmacy from an “outperform” rating to a “market perform” rating in a research note on Monday, January 7th. ValuEngine cut Diplomat Pharmacy from a “sell” rating to a “strong sell” rating in a research note on Monday, February 4th. Robert W. Baird upgraded Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and upped their target price for the stock from $10.00 to $15.00 in a research note on Friday, December 7th. Zacks Investment Research cut Diplomat Pharmacy from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 27th. Finally, Morgan Stanley lowered their price target on shares of Diplomat Pharmacy from $20.00 to $18.00 and set an “equal weight” rating for the company in a report on Monday, December 3rd.

NYSE DPLO traded down $0.01 on Friday, hitting $13.89. 344,800 shares of the company’s stock were exchanged, compared to its average volume of 614,410. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.95 and a quick ratio of 0.66. Diplomat Pharmacy has a 52 week low of $12.30 and a 52 week high of $28.74. The stock has a market capitalization of $1.03 billion, a PE ratio of 16.54 and a beta of 0.98.

Several large investors have recently made changes to their positions in DPLO. Geode Capital Management LLC increased its holdings in Diplomat Pharmacy by 13.4% in the fourth quarter. Geode Capital Management LLC now owns 598,753 shares of the company’s stock valued at $8,059,000 after purchasing an additional 70,528 shares during the period. Tekla Capital Management LLC increased its holdings in Diplomat Pharmacy by 15.2% in the fourth quarter. Tekla Capital Management LLC now owns 505,701 shares of the company’s stock valued at $6,807,000 after purchasing an additional 66,700 shares during the period. Dimensional Fund Advisors LP increased its holdings in Diplomat Pharmacy by 22.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,128,358 shares of the company’s stock valued at $28,650,000 after purchasing an additional 395,246 shares during the period. Great West Life Assurance Co. Can increased its holdings in Diplomat Pharmacy by 8.7% in the fourth quarter. Great West Life Assurance Co. Can now owns 71,458 shares of the company’s stock valued at $886,000 after purchasing an additional 5,702 shares during the period. Finally, Blueshift Asset Management LLC acquired a new stake in Diplomat Pharmacy in the fourth quarter valued at $304,000. Institutional investors own 81.89% of the company’s stock.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Recommended Story: Options Trading

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.